Claimed effect · Tirzepatide

Does Tirzepatide help with body weight?

A
Grade A — established in humans10+ RCTs · effect size: large
Short answerEstablished in humans. 10+ RCTs point the same way: a large effect. SURMOUNT-1: −20.9% at 72 weeks on 15 mg vs −3.1% placebo in 2,539 adults. SURMOUNT-5 head-to-head: −20.2% vs −13.7% on semaglutide at 72 weeks.

What the studies show

SURMOUNT-1: −20.9% at 72 weeks on 15 mg vs −3.1% placebo in 2,539 adults. SURMOUNT-5 head-to-head: −20.2% vs −13.7% on semaglutide at 72 weeks.

Several well-run randomised trials in people, pointing the same way. You can plan around this. It still says nothing about whether the effect is worth the side effects for you.

  1. 1
    Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1).N Engl J Med, 2022;387:205–2162,539 adults; −20.9% at 72 weeks on 15 mg.
  2. 2
    Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5).N Engl J Med, 2025;393(1):26–36751 adults, 72 weeks; −20.2% vs −13.7%; waist −18.4 cm vs −13.0 cm.

In context

Tirzepatide is a once-weekly peptide that activates both GIP and GLP-1 receptors. It is approved for type 2 diabetes, weight management and obstructive sleep apnoea, and in the only direct head-to-head trial it produced more weight loss than semaglutide (20.2% vs 13.7% at 72 weeks) with a similar side-effect profile. It is a prescription medicine; versions sold outside that channel are unlicensed.

Tirzepatide is approved (rx). Legal status differs by country — see the regulation section or the jurisdiction pages.

Questions

Is Tirzepatide proven to help with body weight?
Yes, as far as human trials can show it: 10+ RCTs. LYO grades this outcome A.
What studies are behind the grade?
SURMOUNT-1: −20.9% at 72 weeks on 15 mg vs −3.1% placebo in 2,539 adults. SURMOUNT-5 head-to-head: −20.2% vs −13.7% on semaglutide at 72 weeks.
Is Tirzepatide approved for this?
Tirzepatide is an approved medicine (Approved (Rx)); whether this particular outcome is a licensed indication is stated on the compound page's regulation section.

Other outcomes for Tirzepatide

Reviewed 2 September 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →